Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) had its price target dropped by stock analysts at HC Wainwright from $7.00 to $1.50 in a report released on Monday. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 307.28% from the stock’s current price.

A number of other research firms also recently issued reports on RTTR. Zacks Investment Research downgraded shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Chardan Capital cut their target price on shares of Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a research report on Tuesday, August 8th. Finally, Maxim Group restated a “hold” rating on shares of Ritter Pharmaceuticals in a research report on Wednesday, July 5th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $3.58.

Shares of Ritter Pharmaceuticals (RTTR) opened at 0.3683 on Monday. Ritter Pharmaceuticals has a 52-week low of $0.32 and a 52-week high of $3.75. The company’s market capitalization is $5.43 million. The firm’s 50 day moving average is $0.45 and its 200-day moving average is $0.45.

Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.14). Equities research analysts anticipate that Ritter Pharmaceuticals will post ($0.42) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/23/ritter-pharmaceuticals-inc-rttr-price-target-cut-to-1-50-by-analysts-at-hc-wainwright.html.

A number of institutional investors have recently added to or reduced their stakes in the business. KCG Holdings Inc. lifted its position in Ritter Pharmaceuticals by 259.0% during the 1st quarter. KCG Holdings Inc. now owns 105,409 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 76,046 shares during the period. Alyeska Investment Group L.P. acquired a new position in Ritter Pharmaceuticals during the 4th quarter valued at about $1,768,000. Knoll Capital Management LP acquired a new position in Ritter Pharmaceuticals during the 3rd quarter valued at about $869,000. Finally, Baker BROS. Advisors LP acquired a new position in Ritter Pharmaceuticals during the 3rd quarter valued at about $672,000. Institutional investors own 7.55% of the company’s stock.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.